Early trial tests Two-Drug attack on blood cancer
NCT ID NCT03447808
Summary
This early-stage study is testing the safety and effectiveness of combining two drugs, daratumumab and ibrutinib, for people with chronic lymphocytic leukemia (CLL) who have symptoms but have not yet received any treatment. The goal is to see if using these drugs together works better than using them separately. Researchers will closely monitor 15 participants for side effects and how well the cancer responds.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.